Table 2 Treatment outcome on day 28, according to treatment arm at four sites in Mozambique, 2018
Artemether–lumefantrine | Study site | ||||
|---|---|---|---|---|---|
Massinga (N = 95) | Moatize (N = 92) | Montepuez (N = 90) | Mopeia (N = 91) | Total (N = 368) | |
ACPR (uncorrected) n | 62 | 79 | 80 | 64 | 285 |
ETF | 0 | 0 | 0 | 0 | 0 |
LCF | 8 | 0 | 0 | 15 | 23 |
LPF | 15 | 2 | 3 | 5 | 25 |
New infections (with PCR) | 20 | 2 | 3 | 17 | 42 |
Recrudescences (with PCR) | 3 | 0 | 0 | 3 | 6 |
Undetermined (with PCR) | 0 | 0 | 0 | 0 | 0 |
No treatment outcome (lost to follow-up or withdrawn) | 10 | 11 | 7 | 7 | 35 |
PP day 28 efficacy (PCR-uncorrected) n/N (%) [95%CI] | 62/85 (72.9) [62.2–82.0] | 79/81 (97.5) [91.4–99.7] | 80/83 (96.4) [89.8–99.2] | 64/84 (76.2) [65.6–84.8] | 285/333 (85.6) [81.3–89.2] |
PP day 28 efficacy (PCR-corrected) n/N (%) [95%CI] | 62/65 (95.4) [87.1–99] | 79/79 (100) [95.4–100] | 80/80 (100) [95.5–100] | 64/67 (95.5) [87.5–99.1] | 285/291 (97.9) [95.6–99.2] |
Artesunate–amodiaquine | Massinga (N = 92) | Moatize (N = 0) | Montepuez (N = 90) | Mopeia (N = 91) | Total (N = 273) |
|---|---|---|---|---|---|
ACPR (uncorrected) n | 85 | NA | 89 | 82 | 256 |
ETF | 0 | NA | 0 | 0 | 0 |
LCF | 0 | NA | 0 | 2 | 2 |
LPF | 1 | NA | 0 | 0 | 1 |
New infections (with PCR) | 0 | NA | 0 | 1 | 1 |
Recrudescences (with PCR) | 0 | NA | 0 | 1 | 1 |
Undetermined (with PCR) | 1 | NA | 0 | 0 | 1 |
No treatment outcome (loss to follow-up or withdrawn) | 6 | NA | 1 | 7 | 14 |
PP day 28 efficacy (PCR-uncorrected) n/N (%) [95%CI] | 85/86 (98.8) [93.7–100] | NA | 89/89 (100) [95.9–100] | 82/84 (97.6) [91.7–99.7] | 256/259 (98.8) [96.7–99.8] |
PP day 28 efficacy (PCR-corrected) n/N (%) [95%CI] | 85/85 (100) [95.8–100] | NA | 89/89 (100) [95.9–100] | 82/83 (98.8) [93.5–100] | 256/257 (99.6) [97.9–100] |